Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vivalis has granted Acambis rights to the avian embryonic stem cell derived eb66 cell line to evaluate it as a production platform of viral vectors and vaccines.
Subscribe to our email newsletter
Franck Grimaud, CEO of Vivalis, said: “Vivalis is pleased to enter in this agreement to support Acambis’s R&D efforts for the development of new vaccines.
“With already more than 30 different vaccines evaluated or developed on Vivalis eb66 cell line, we strongly believe that this cell line has the potential to replace the eggs, and to become a standard cell substrate for vaccines production in the foreseeable future.”